Risk Of Developing Liver Cancer After HCV Treatment

Friday, December 10, 2010

Hepatitis C: Geno 1a had a more significant SVR Then Geno 1b To Peg/Riba

Influence of HCV Genotype 1a and Genotype 1b on the virological response to antiviral therapy.


Adriano M. Pellicelli1, Mario Romano2, Giorgio -. Barbarini3, Ettore Mazzoni4, Fabrizio Mecenate5, Caterina Furlan6, Antonio Picardi7, Maria Elena Bonaventura8, Giuseppe Barbaro9, Roberto Villani1, Cecilia D'Ambrosio1, Paolo Guarascio1, Lucia Fondacaro1, Giuseppe Cerasari1, Angela Elena Lusi10, Arnaldo Andreoli1, Fabrizio Soccorsi11. Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. 2. Liver Unit, Ospedale Sandro Pertini, Rome, Italy, Italy. 3. Infectious and Parasitic Diseases , Policlinico San Matteo, Pavia, Italy, Italy. 4. Liver Unit, Policlinico Casilino Hospital , Rome, Italy, Italy. 5. Liver Unit, Villa Betania Hospital , Rome, Italy, Italy. 6. Infectious and Tropical Diseases , University “La Sapienza', Rome, Italy, Italy. 7. Clinical Medicine , Campus Bio-Medico University , Rome, Italy, Italy. 8. Infectious Disease , Ospedale San Camillo de Lellis , Rieti, Italy, Italy. 9. Department of Medical Pathophysiology , University “La Sapienza” , Rieti, Italy, Italy. 10. Immunology, Red Cross, Rome, Italy, Italy. . ,


Aim:
We have analyzed if, in genotype 1 HCV infected patients, antiviral treatment with pegylated interferon plus ribavirin has the same efficacy in term of sustained virological response (SVR) in subtypes 1a respect to 1b and if these two populations of patients have different clinical characteristics...


Methods and Patients:
Three hundred and one naïve patients with genotype 1 chronic active hepatitis C received peginterferon alfa 2a or alfa 2b plus ribavirin (15mg/kg/day) for 48 weeks.
The primary end point was SVR by intention to treat. . ;.


Results:
.All the demographic and clinical characteristics of the patients are reported in the Table Below.

;


SVR was achieved in 56% (71 pts) of patients with subtype 1a and in 38% (66 pts) of patients with subtype 1b (p less then 0.001). ;


The percentage of patients who first achieved undetectable HCV RNA at weeks 4 and 12 were respectively 49% and 58% in subtype 1a and 35% and 41% in subtype 1b. .'


;.,Logistic regression analysis identified an HCVRNA less then 400000 IU/ml (OR 3.5 95% CI 1.5-7.3 p less then 0.001) and Fibrosis score less then 2 (OR 4.2, 95% CI 3.3-7.5 p less then 0.001) as independent parameters for SVR in subtype 1a HCV infected patients.
'.
Conclusion:
Compared to patients with genotype 1b, the patients with genotype 1a had a more significant SVR.
.
HCV RNA (Viral Load) less then 400000 UI/ml and lower fibrosis score were independent parameters predictive of SVR in genotype 1a patients.


From The AASLD 2010 Abstract # 983.

No comments:

Post a Comment